Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Stimulation Protocols With GnRH Antagonists:Focusing on MicroRNA
NCT01510054 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2025-07-23
Summary
MiRNAs are single-stranded small non-coding RNAs that act on specific mRNAs to regulate the gene expression. Studies have suggested that miRNAs influence cellular activities in the uterus, including cell differentiation and embryo implantation.
In assisted reproductive cycles, controlled ovarian stimulation (COS) results in supraphysiological steroid levels and is associated with very low luteinizing hormone concentration during the luteal phase, the peri-implantation and implantation period. Luteal phase support, administration of medication aimed at supporting the implantation process, has been a routine practice in in vitro fertilization (IVF) clinics. Luteal phase support with steroid hormone has been found to improve pregnancy rates when human menopausal gonadotropins were used in conjunction with GnRH agonists for ovarian stimulation and IVF. Reports on effect of steroid supplementation in GnRH antagonist protocols are limited.
The proposed project is an extension of our previous study on Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Hyperstimulation Protocols with Gonadotropin Releasing Hormone Antagonists. The significance of this study is based on the importance of luteal phase endometrial after COS for the process of implantation. The availability of oocycte donors in assisted reproduction technology programs offers a unique opportunity to study the impact of different stimulation protocols on the quality of the luteal phase. In addition, the oocyte donor model may allow us to evaluate the impact of different luteal support protocols directly on the endometrial preparation by histological as well as biochemical markers.
Study design: Study subjects underwent ovarian stimulation according to a gonadotropin/GnRH antagonist protocol. All donors had a baseline measurement of serum follicle stimulating hormone (FSH) and estradiol levels on the second day of their menstrual cycles. Provided serum FSH levels were less than 10mIU/ml and E2 levels were less than 60pg/ml, ovarian stimulation was initiated with recombinant FSH. The daily dose was adjusted according to follicular development by serial transvaginal ultrasound and serum E2 response. A daily evening dose of ganirelix acetate was initiated on the 6th day of stimulation and continued through the day of human chorionic gonadotropin administration. When at least three follicles reached a mean diameter of 18mm, ovulation was triggered with a single dose of Human chorionic gonadotropin (hCG). Sonographically guided transvaginal oocyte retrieval was performed 34-36 hours after the hCG administration.
Thirty endometrial biopsies from oocyte donors on their COS cycles will be used for the study. Study subjects have been randomized into 4 groups. Grp 1: day of retrieval, did not receive any luteal-phase support, which serves as base line; grp2: 3, 5 and 10 days after retrieval with no luteal phase support, which serves as control; grp3: 3, 5 and 10 days after retrieval, luteal phase support with progesterone in the form of vaginal suppositories starting from the day after retrieval; grp4: daily oral dose of 2 mg 17β-estradiol in addition to the micronized progesterone. Immediately after the endometrial biopsy all specimens were stored in liquid nitrogen tanks at -196°C.
Total RNA will be isolated and microarray will be performed using an Illumina miRNA expression panel. Array results will be compiled and analyzed focusing on the following aspects: the target genes of prominent miRNAs, miRNA profile in relation to target gene pathways; miRNA expression profile in relation to endometrial dating and status; effect of luteal phase support on miRNA expression after ovarian stimulation. Minimum of 3 miRNA arrays will be run for each sample for the purpose of statistical analysis. A total of 30 arrays will be needed for all samples from all groups.
In this study, the investigators pose three questions: 1) How many and what types of miRNAs are in the endometrium during ovarian stimulation? This is to identify miRNAs and associated target genes that are relevant for endometrium receptivity; 2) Do levels of miRNA expression change during the luteal phase, or during the window of implantation? This is to examine the dynamics of miRNAs that are associated with remodeling process of endometrium; and 3) Do luteal phase support alter miRNA expression in the luteal phase? This is to investigate the steroid effect on miRNA regulation. The investigators hypothesize that many critical genes related to implantation are regulated by miRNAs. This research effort will potentially advance our knowledge of endometrial characteristics after COS and the impact of sex steroid supplementation. Overall the study should help better understand the genetic control of implantation. Completion of this study may also provide measurable scientific evidence and useful information for the management of IVF cycles.
Conditions
- Controlled Ovarian Stimulation
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Yulian Zhao, Ph.D · Johns Hopkins University
Eligibility
- Min Age
- 21 Years
- Max Age
- 31 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2002-07-31
- Primary Completion
- 2014-11-30
- Completion
- 2014-11-30
Countries
- United States
Study Locations
More Related Trials
-
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
NCT04108039 ·Status: COMPLETED ·Phase: NA
-
Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS
NCT02827656 ·Status: UNKNOWN ·Phase: NA
-
Luteal Phase Support With Daily Administration of Gonadotropin-releasing Hormone Agonist Compared to Progesterone/Estradiol in IVF/ICSI Cycles With Ovulation Triggering With GnRH-a
NCT05143723 ·Status: UNKNOWN ·Phase: PHASE2
-
Impact of Gonadotrophin Releasing Hormone Analogues on Oocyte and Embryo Quality
NCT03139474 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response
NCT04549649 ·Status: COMPLETED ·Phase: NA
-
Progesterone Primed Ovarian Stimulation Protocol Versus Antagonist Protocol for PCO Patient
NCT05847660 ·Status: UNKNOWN ·Phase: NA
-
Antagonist/Letrozole in Poor Responders
NCT00823004 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support
NCT05286554 ·Status: COMPLETED ·Phase: PHASE4
-
Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)
NCT00954811 ·Status: UNKNOWN ·Phase: PHASE4
-
Optimizing Ovulation Induction in the Poor Responder
NCT01200537 ·Status: WITHDRAWN ·Phase: NA
-
GnRH Agonist (GnRHa) Withdrawal at Late Stage of Long Protocol and the Incidence of Ovarian Hyper-stimulation
NCT01634724 ·Status: UNKNOWN ·Phase: NA
-
Luteal Phase Support In IVF Women Using GnRH Agonist
NCT04174378 ·Status: COMPLETED
-
Prolonged Protocol of Early Follicular or Mid Luteal Phase
NCT04522479 ·Status: UNKNOWN ·Phase: NA
-
Recombinant LH Supplementation Timing Strategies (From Day 1 or Day 6) to a Standard GnRH Agonist Long Protocol in Subsequent COS Cycle of Older Patients With Unexpected Poor or Suboptimal Ovarian Response
NCT04178135 ·Status: UNKNOWN ·Phase: NA
-
LATE LUTEAL PHASE VS. CONVENTIONAL EARLY FOLLICULAR PHASE START IN IVF
NCT06551376 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women
NCT00565240 ·Status: COMPLETED ·Phase: NA
-
Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome
NCT02022241 ·Status: UNKNOWN ·Phase: NA
-
Growth Hormone Co-treatment Within a GnRH Antagonist Protocol in Patients With Poor Ovarian Response
NCT03373149 ·Status: UNKNOWN ·Phase: PHASE2
-
Luteal Phase-start Ovarian Stimulation With Corifollitropin Alfa
NCT03555942 ·Status: COMPLETED ·Phase: NA
-
Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation
NCT02703584 ·Status: COMPLETED ·Phase: PHASE4
-
Luteal Phase Estradiol Support for In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles
NCT02677259 ·Status: UNKNOWN ·Phase: PHASE2
-
Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles
NCT06150703 ·Status: RECRUITING ·Phase: PHASE3
-
Effect of Luteal Progesterone Support on Pregnancy Rates With Combined Clomid/ Gonadotropin & IUI
NCT02510534 ·Status: TERMINATED ·Phase: PHASE1
-
Effect of Controlled Ovarian Stimulation in Quality of Oocyte and Embryo
NCT04539067 ·Status: UNKNOWN ·Phase: PHASE2
-
Short-Term Androgen Priming Before COS Using Aromatase Inhibitor and hCG During Early-Follicular-Phase GnRH Antagonist Administration - a Randomized Controlled Trial
NCT00286364 ·Status: COMPLETED ·Phase: PHASE4